<DOC>
	<DOCNO>NCT00704301</DOCNO>
	<brief_summary>Delirium Intensive Care ( IC ) patient frequent disorder . The aim study investigate whether treatment delirium ICU rivastigmine add haloperidol shortens duration delirium comparison placebo add treatment haloperidol .</brief_summary>
	<brief_title>Rivastigmine Intensive Care Unit ( ICU ) Delirium</brief_title>
	<detailed_description>Objective : To study whether rivastigmine add treatment haloperidol shorten duration delirium ICU patient reduce cost . Study design : Multicentre , double-blind , randomize control trial . Study population : Consecutive adult ICU patient delirium accord CAM-ICU . Intervention : Increasing dosage rivastigmine placebo add-on medication . Primary study parameter : Duration delirium . Secondary study parameter : Delirium severity , length ICU hospital stay , functional status mortality 3 month . Sample size : 440 patient include . Economic evaluation : include comparison direct indirect medical cost . Nature extent burden risk associate participation , benefit group relatedness : Burden : questionnaire ( duration : 30 minute ) . Risk : possible exposure drug indicate disorder . Benefit : possible treatment accord expert possible beneficial drug . Consideration : The investigator study believe burden risk exceed expect benefit .</detailed_description>
	<mesh_term>Delirium</mesh_term>
	<mesh_term>Rivastigmine</mesh_term>
	<criteria>18 year older Positive CAMICU Known allergy rivastigmine Unable receive enteric medication Pregnant lactate Renal replacement therapy Hepatic encephalopathy Second third degree atrioventricular block Uncertainty diagnosis delirium confirmation neurologist , psychiatrist geriatrician Parkinson 's disease . Lewy body dementia . ECG QT interval 500 msec . No informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>Delirium</keyword>
	<keyword>Confusion</keyword>
</DOC>